Unknown

Dataset Information

0

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study.


ABSTRACT: Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R2 = 0.080-0.921), TICs (Cohen's  κ = 0.175-0.396) and NTICs (κ = 0.004-0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.

SUBMITTER: Pinato DJ 

PROVIDER: S-EPMC6738063 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10884007 | biostudies-literature
| S-EPMC6547269 | biostudies-literature
| S-EPMC6854886 | biostudies-literature
| S-EPMC5880102 | biostudies-literature
| S-EPMC7905537 | biostudies-literature
| S-EPMC7763211 | biostudies-literature
| S-EPMC5805531 | biostudies-literature
| S-EPMC8566736 | biostudies-literature
| S-EPMC8293136 | biostudies-literature
| S-DIXA-D-1017 | biostudies-other